161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Reports First Quarter 2026 Financial Results and Business Highlights
Annual Report to Security Holders
Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Material disclosure
U.S. FDA Approval of AVLAYAH⢠(tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence